DE60237162D1 - Liposomenladung mit metallionen - Google Patents

Liposomenladung mit metallionen

Info

Publication number
DE60237162D1
DE60237162D1 DE60237162T DE60237162T DE60237162D1 DE 60237162 D1 DE60237162 D1 DE 60237162D1 DE 60237162 T DE60237162 T DE 60237162T DE 60237162 T DE60237162 T DE 60237162T DE 60237162 D1 DE60237162 D1 DE 60237162D1
Authority
DE
Germany
Prior art keywords
liposomenic
metallions
loading
liposomes
encapsulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237162T
Other languages
English (en)
Inventor
Paul Tardi
Sharon Johnstone
Murray Webb
Marcel Bally
Sheela Abraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celator Pharmaceuticals Inc
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60237162D1 publication Critical patent/DE60237162D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE60237162T 2001-10-03 2002-10-03 Liposomenladung mit metallionen Expired - Lifetime DE60237162D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32667101P 2001-10-03 2001-10-03
US34152901P 2001-12-17 2001-12-17
US35675902P 2002-02-15 2002-02-15
US36207402P 2002-03-07 2002-03-07
US39427302P 2002-07-09 2002-07-09
PCT/CA2002/001501 WO2003028697A2 (en) 2001-10-03 2002-10-03 Liposome loading with metal ions

Publications (1)

Publication Number Publication Date
DE60237162D1 true DE60237162D1 (de) 2010-09-09

Family

ID=27541066

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237162T Expired - Lifetime DE60237162D1 (de) 2001-10-03 2002-10-03 Liposomenladung mit metallionen

Country Status (11)

Country Link
US (3) US7238367B2 (de)
EP (1) EP1432403B1 (de)
JP (2) JP4822666B2 (de)
AT (1) ATE475411T1 (de)
AU (1) AU2002331481B2 (de)
CA (1) CA2462376C (de)
DE (1) DE60237162D1 (de)
HK (1) HK1066731A1 (de)
IL (2) IL161187A0 (de)
TW (1) TWI235066B (de)
WO (1) WO2003028697A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100489701B1 (ko) * 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
KR20060034215A (ko) * 2003-03-31 2006-04-21 알자 코포레이션 비대칭 지질 코팅을 가지는 지질 입자 및 그 제조 방법
WO2004087115A2 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination compositions of camptothecins and fluoropyrimidines
EP1608338A1 (de) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmazeutische zusammensetzungen enthaltend wirkstoffe mit einer lactongruppe und übergangsmetallionen
PT1744764E (pt) * 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
JP4885715B2 (ja) 2004-06-01 2012-02-29 テルモ株式会社 イリノテカン製剤
CA2572865C (en) * 2004-07-09 2017-07-25 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
EP1796729A4 (de) * 2004-10-06 2010-12-08 Bc Cancer Agency Liposome mit verbesserter arzneirückhaltung zur behandlung von krebs
CA2584279C (en) * 2004-11-05 2015-01-27 Index Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
EP1817005A1 (de) * 2004-11-18 2007-08-15 Celator Pharmaceuticals, Inc. Verfahren zum beladen von abgabetransportmitteln mit mehrfachen wirkstoffen
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
EP1976485A4 (de) * 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc Liposomale formulierungen mit sekundären und tertiären aminen und herstellungsverfahren dafür
WO2008005045A2 (en) * 2005-12-30 2008-01-10 Dermazone Solutions, Inc. Nanolipidic particles
JP5484059B2 (ja) * 2006-10-06 2014-05-07 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 脊髄核インプラント
US8241648B2 (en) 2007-03-02 2012-08-14 Luna Innovations Incorporated Amphiphilic or lipophilic polar functionalized fullerenes and their uses
EP2187869B1 (de) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Verbesserte platin-arzneimittelformulierungen
KR101085824B1 (ko) * 2009-03-11 2011-11-23 한국유나이티드제약 주식회사 생체적합성 고분자를 이용한 다기능성 조영제 및 이의 제조방법
US9814657B2 (en) * 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
US10688026B2 (en) 2009-04-27 2020-06-23 Premier Dental Products Company Buffered microencapsulated compositions and methods
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
JP2012236772A (ja) * 2009-09-28 2012-12-06 Terumo Corp スピカマイシン誘導体を有するリポソーム製剤
WO2011109334A2 (en) * 2010-03-01 2011-09-09 The Regents Of The University Of California Localization of agents at a target site with a composition and an energy source
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
PL226015B1 (pl) * 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
KR101371698B1 (ko) * 2011-06-30 2014-03-07 한국화학연구원 진단 및 치료를 위한 이중기능성 리포솜 및 그의 제조방법
HUE045978T2 (hu) 2011-10-21 2020-01-28 Jazz Pharmaceuticals Res Llc Liofilizált liposzómák
EP2771034B1 (de) * 2011-10-25 2018-08-08 Nektar Therapeutics Topoisomerase-i und -ii hemmer zur anwendung bei der behandlung von krebspatienten
AU2013292636A1 (en) 2012-07-18 2015-02-05 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
ES2442450B1 (es) * 2012-08-09 2014-12-12 Enoc Solutions, S.L. Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
EP3470061A1 (de) 2012-11-20 2019-04-17 Spectrum Pharmaceuticals, Inc. Verbessertes verfahren zur herstellung ein dosierung von in liposomen verkapseltem vincristin zur therapeutischen verwendung
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
AU2015320595B2 (en) 2014-09-25 2021-01-21 Premier Dental Products Company Bondable microcapsules and surface functionalized fillers
WO2016069740A1 (en) * 2014-10-29 2016-05-06 The Regents Of The University Of California Bioactive delivery vehicles
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CA3001467A1 (en) 2015-10-16 2017-04-20 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
MX2022016063A (es) 2020-06-18 2023-04-11 Akagera Medicines Inc Compuestos de oxazolidinona, composiciones de liposomas que comprenden compuestos de oxazolidinona y metodos de uso de los mismos.
MX2023001274A (es) 2020-07-28 2023-04-24 Jazz Pharmaceuticals Ireland Ltd Sintesis quiral de inhibidores de raf biciclicos fusionados.
CA3187514A1 (en) 2020-07-28 2022-02-03 Andrew BELFIELD Fused bicyclic raf inhibitors and methods for use thereof
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) * 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
JPS5933287A (ja) * 1982-08-19 1984-02-23 Hidetoshi Tsuchida 対面型ポルフイリン金属錯体を包接したリン脂質リポソ−ムおよび酸素吸脱着剤
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
JPH0639382B2 (ja) * 1985-03-29 1994-05-25 財団法人生産開発科学研究所 リン脂質リポソ−ム
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4898735A (en) * 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
EP0478702B1 (de) * 1989-06-22 1994-12-07 Vestar, Inc. Einkapselverfahren
US5010073A (en) 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5270053A (en) * 1990-04-03 1993-12-14 Ciba-Geigy Corp. Parenterally administerable liposome formulation comprising synthetic lipid
DE4134158C2 (de) * 1991-10-11 1997-02-13 Max Delbrueck Centrum Verwendung von Carboplatin in lyotrophen Mesophasen zur Überwindung einer durch Zytostatika ausgelösten Leukopenie
EP0645048A1 (de) * 1992-06-08 1995-03-29 BioQuest Incorporated Herstellung anorganischer teilchen von kontrollierter grösse zur verwendung in trennverfahren, als magnetische molekulare schalter und als anorganischeliposomen für medizinische anwendungen
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US6274116B1 (en) * 1993-06-03 2001-08-14 Reagents Of The University Of California Compositions for boron delivery to mammalian tissue
CA2126648C (en) * 1993-11-09 2000-10-10 Tomas De Paoli Liposomes containing bioavailable iron (ii) and method for obtaining them
DE4341479A1 (de) * 1993-12-02 1995-06-08 Deutsches Rheuma Forschungszen Verwendung von Metallothioneinen oder deren Apothioneinen zur Herstellung von Arzneimitteln mit antiviraler Wirkung
US5466467A (en) 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
GB9500116D0 (en) 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US5843475A (en) * 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
WO1999059545A1 (en) * 1998-05-19 1999-11-25 Sdg, Inc. Targeted liposomal drug delivery system
AU2001258106A1 (en) 2000-05-11 2001-11-20 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
WO2001089653A2 (en) * 2000-05-23 2001-11-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Immobilized metalchelate complexes for catalysis and decontamination of pesticides and chemical warfare nerve-agents
US6416745B1 (en) * 2001-05-03 2002-07-09 Block Drug Company, Inc. Dental composition for treating hypersensitive teeth

Also Published As

Publication number Publication date
IL161187A (en) 2012-10-31
HK1066731A1 (en) 2005-04-01
EP1432403A2 (de) 2004-06-30
US20030091621A1 (en) 2003-05-15
US7238367B2 (en) 2007-07-03
US7744921B2 (en) 2010-06-29
ATE475411T1 (de) 2010-08-15
CA2462376A1 (en) 2003-04-10
TWI235066B (en) 2005-07-01
AU2002331481B2 (en) 2008-04-24
JP2011157376A (ja) 2011-08-18
CA2462376C (en) 2010-12-14
EP1432403B1 (de) 2010-07-28
JP2005508921A (ja) 2005-04-07
US20080044464A1 (en) 2008-02-21
JP4822666B2 (ja) 2011-11-24
US20060193904A1 (en) 2006-08-31
IL161187A0 (en) 2004-08-31
WO2003028697A3 (en) 2003-05-30
WO2003028697A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
DE60237162D1 (de) Liposomenladung mit metallionen
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
DE69907977D1 (de) Pyrrolobenzodiazepine
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
DE60121953D1 (de) Herstellungsverfahren von arzneizubereitungen
DE602004026113D1 (de) Glp-1-verbindungen
DE50104210D1 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
NO20044916L (no) Preparater av sulfinylacetamid
ATE330017T1 (de) Kallikrein gen
DE60126814D1 (de) Inhalation von stickoxid
SE9901077D0 (sv) Novel use
NO20031860D0 (no) Kahalaolid F
ATE439828T1 (de) In der mundhíhle dispergierbare feste pharmazeutische form
SE0300826L (sv) Leverans av emulsionssprängämnen
DE602004015504D1 (de) Von injektionspräparaten
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
DE60025494D1 (de) Epothilon zusammensetzungen
DE60230292D1 (de) Aktivsauerstoff erzeugendes material
ATE395917T1 (de) Kombination von docetaxel mit flavopiridol
MY137953A (en) New association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent
ITTO20000068V0 (it) Plantaroller massaggiatore, distensore e stimolatore dell'arco plantare.
ITMI20011561A0 (it) Nuove composizioni con fosfolipidi biologicamente attivi
UA6487S (uk) Прапор